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Mesenchymal stromal cells (MSC) have essential functions in building and supporting
the tumour microenvironment, providing metastatic niches, and maintaining cancer
hallmarks, and it is increasingly evident that the study of the role of MSC in cancer
is crucial for paving the way to clinical opportunities for novel anti-cancer therapies.
To date, the vast majority of preclinical models that have been used for studying
the effect of reactive MSC on cancer growth, metastasis, and response to therapy
has been mainly based on in vitro flat biology, including the co-culturing with cell
compartmentalization or with cell-to-cell contact, and on in vivo cancer models with
different routes of MSC inoculation. More complex in vitro 3D models based on spheroid
structures that are formed by intermingled MSC and tumour cells are also capturing
the interest in cancer research. These are innovative culture systems tailored on the
specific tumour type and that can be combined with a synthetic extracellular matrix,
or included in in silico technologies, to more properly mimic the in vivo biological, spatial,
biochemical, and biophysical features of tumour tissues. In this review, we summarized
the most popular and currently available preclinical models for evaluating the role of
MSC in cancer and their specific suitability, for example, in assaying the MSC-driven
induction of epithelial-to-mesenchymal transition or of stem-like traits in cancer cells.
Finally, we enlightened the need to carefully consider those parameters that might
unintentionally strongly affect the secretome in MSC-cancer interplay and introduce
confounding variables for the interpretation of results.
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INTRODUCTION
Cancer is a complex disease that thrives in a heterogeneous and adaptive tumour
microenvironment (TME) admixed with reactive elements surrounding or infiltrating the
tumour cells. Among these, endothelial, immune, and mesenchymal stromal cells (MSC) or
cancer-associated fibroblasts (CAF) are frequently observed, playing an important role during
carcinogenesis and cancer progression (1, 2). As a part of the tumour-supporting mesenchymal
stroma, CAF have been suggested to originate from MSC, thereby sharing several features
(3–5). For the distinguishing between MSC and CAF we recommend other previous review (5),
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since in this review, we will focus on MSC. Regardless the
tissue origins, MSC are inherently tumour-homing and are a
considerable component of the general host response to tissue
damage caused by cancer cells. Cancer has been associated with
MSC at all stages of disease progression with contradicting
conclusions. Indeed, MSC have been also shown to have anti-
cancer activities (6). More often, MSC are considered a foe in
cancer for the immunosuppressive ability that creates a protective
milieu for tumour cells by recruiting immunosuppressive
tumour-associated macrophage TAM (7), for the promotion
of tumour angiogenesis, proliferation, and metastasis, but also
tumour dormancy and drug resistance (5).
CSC AND MSC
Under physiological conditions, MSC have a major role in the
maintenance of stem cell niches, like for the hematopoietic
niche (8). Similarly, in cancer, MSC are relevant for the
formation and maintenance of cancer stem cells (CSC). CSC
are considered quiescent cells that have been isolated from a
number of tumours (e.g., hematopoietic malignancies, breast
carcinoma, glioblastoma, and sarcomas) by using different
techniques (9–12).
Research on CSC has defined them as the driving force
in tumour formation as they are characterized by self-renewal
ability and can give rise to heterogeneous lineages that
recapitulate the main tumour features (13). Yet, it has gradually
become clear that CSC, like normal stem cells, do not necessarily
have to be rare and/or quiescent; multiple examples now show
that they can be abundant and can proliferate vigorously.
Furthermore, it is emerging that stem cell hierarchies may be
much more plastic than previously appreciated, a phenomenon
that complicates the identification and eradication of CSC (14).
Despite recent data are therefore questioning the validity of
the CSC model, the CSC-MSC interaction is well documented
and is crucial for 3D growth and stemness of tumour cells (15),
or for the generation of an hybrid MSC-CSC cell populations,
occurring via entosis, i.e., a form of cell-to-cell internalization,
or via fusion, as demonstrated in different tumours (16–20).
Indeed, the selection processes of hybrid cells after MSC–tumour
cell fusion contribute to CSC development (20, 21). CSC-MSC
interaction occurs via soluble factors (22), exosomes, or direct
interaction (23). Another form of contact has been described
for glioblastoma, where the CSC state is regulated by a transient
interaction between cancer cells and platelets. This contact
induces an epithelial-to-mesenchymal (EMT) transition program
leading to the expression of mesenchymal features which may
coincide with a CSC-like state. In turn, once CSC have seeded
a distant organ, they can orchestrate stromal cells to their needs
(23) as CSCmay promote, as an example, the release of TGF-β by
MSC that further fosters EMT and increases the CSC stem-like
state (24).
Given their mesenchymal origin, EMT cannot be proposed
in sarcomas. However, after we demonstrated the existence of
CSC (25), we showed that, by using a 2D co-culture system
that also included CSC spheroids, MSC increased the CSC
migratory capacity via TGF-β1 that, in turn, stimulated the
secretion of the pro-inflammatory cytokine IL-6 that fostered
osteosarcoma stemness and aggressiveness (26). Blocking the
TGF- β1 signalling pathway in the same MSC-CSC co-cultures
inhibited the CSC dedifferentiation, clonogenicity, and self-
renewal capacity (27).
It follows that the study of the interaction between MSC
and cancer cells, with or without stem-like properties, is crucial
to bring out clinical opportunities for new cancer therapies.
However, the set up of the appropriate models according to the
specific study aim is crucial. Here, we summarized the currently
available and most popular preclinical models and their specific
features for modelling MSC-cancer cells interplays.
IN VITRO MODELS
The set up of pre-clinical models with MSC requires in vitro
expansion thereby possibly causing meaningful changes in MSC
behaviour, and affecting the interpretation of results. However,
this is a bias that, to date, cannot be overcome tomeet the demand
for MSC-cancer cells preclinical modelling. The current in vitro
preclinical models are mainly based on two-dimensional (2D)
surfaces and include co-culture systems. These type of models
have the enormous advantage to easily allow the control of
the experimental conditions, and the analysis of expression of
specific molecular signalling that can be distinguished between
the two different cell populations. The first and simplest example
is the treatment of cancer cells with conditioned medium of
MSC cultures and is useful to study the effect of MSC-secreted
soluble factors on cancer cell behaviour (28–30). Amore complex
system is based on the use of transwell with the two cell types
seeded onto separate compartments and is suitable for keeping
the reciprocal paracrine interactions for studying the effect of
MSC secretome on tumour migratory, invasive, and stemness
potentials (26, 31, 32). Finally, the co-seeding of the two cell
populations on the same compartment of the culture support
is also possible and has been used, for example, to evaluate the
transfer of mitochondria from MSC to breast carcinoma cells
(33), or to evaluate the metabolic symbiosis (34). Notably, the
co-seeding is the most appropriate 2D approach to resemble
the in vivo phenotype: it allows the cell-to-cell direct contact
interactions. For this model, immunostaining is the easiest way
of analysis, combined with the observation of either fixed or
live cells through confocal or optical microscopes. However, for
more complex molecular analysis, expensive techniques to sort
single cells are needed, like immunomagnetic separation or, after
the cell transfection with a fluorescent reporter, the cell retrieval
by flow cytometry (34, 35). In conclusion, 2D in vitro culture
systems are easily handled but they are falling short in predicting
biological responses since they cannot thoroughly recapitulate
both the complexity and the specificity of living tissues. Indeed,
tumours are not merely clusters of proliferating cancer cells
that grow on plastic 2D surfaces, but rather highly complex
3D structures with a dynamic extracellular matrix (ECM) and
reactive stromal cells with a precise spatial relationship. Thus, 2D
models should be not used for studying complex processes that
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cannot be reproduced in this type of culture, like drug perfusion
in the tissue, intravasion, or extravasion of tumour cells, invasion
of tumour cells through an ECMwith a 3D structure, cytotoxicity
of anticancer-drugs that might be affected by solute or gas
gradient or by different transcriptome or proteome signature that
is affected by the tumour-stroma interaction in 3D structures.
Based on that, significant effort has been put forward to develop
more sophisticated 3D structures, like cells aggregates alone or
combined with bioprinting or microfluidics techniques.
The key point to improve 3D co-culturing model is that
functional unit of the tissue must be considered rather than
single cells, including cell-cell contact and, depending on the
cell types, a polarized morphology, a basement membrane and
an ECM. For a list and brief description of the most commonly
used 3D culturing systems see Table 1. The simplest model of 3D
cultures is based on multicellular tumour spheroids without the
addition of external ECM component. Despite cells can per se
secrete ECM proteins, 3D spheroids are commonly considered
ECM-free models. Spheroid cultures have been established from
several cancers, also to study tumour-MSC interaction, including
glioma, breast, colon, ovary, and prostate carcinoma (36). These
multicellular structuresmimic in vivo growth via the formation of
a central necrotic core, a solute/ion gradient from the periphery
to the centre, and a 3D cellular spatial organization. Forced-
floating, hanging drop spheroids, spheroids obtained by using
bioreactors are examples of this type of cell aggregates mixed with
MSC and tumour cells, at different ratio (e.g., 3:1, respectively)
(36, 37). Forced-floating cell aggregates are obtained by avoiding
cell attachment to the well bottom. The hanging-drop method is
the most widely used and is obtained by seeding a small aliquot of
single-cell suspension in a volume that exceeds the well volume.
By inverting the plate, the volume generates a drop in which
cells are kept in place by surface tension and are then densely
packed in spheroid-like structures with high reproducibility.
Both forced-floating and hanging-drop spheroids are extensively
used for drug screening (38, 39), thanks to the high number of
spheroids/plate that can be obtained and the low cost. On the
contrary, rotating cell culture bioreactor and spinner flasks force
spheroid formation by continuous agitation (37, 40). However,
the different size and the fact that spheroids formed in bioreactors
must be related to be tested for drug screening, makes them
unsuitable for this application. Nevertheless, bioreactors are the
best options when long term culture and carefully monitoring
of the environmental conditions (such as oxygen and nutrients)
are required.
To recreate the interstitial space, it is essential to add
the ECM component to the multicellular spheroids (41).
For this aim, tumour cell and MSC co-cultures can be
admixed to high biocompatible scaffolds of natural origin
(i.g. collagen, hyaluronan, matrigel, elastin), or synthetic
origin (polyethylenglycol, polyvinvyl alcohol, ceramics, or
biomaterials), or also ECM isolated from tumour biopsies to
mimic microenvironmental conditions (42). Within the scaffold,
cells can interact one with the other (essential in the case of
MSC-tumour studies), migrate through the pores and re-create
in vivo-like communication strategies that mimic physiology.
More the used matrix resembles the real tumour matrix and
more predictive is assumed to be the model. For the addition
of ECM in 3D cancer models, 3D bioprinting has stolen the
spotlight since it allows the formation of high-resolution 3D
structures by dispensing cell-laden biomaterials in a precisely
and spatially defined way (43). In this technique, a hydrogel-
like pre-polymer solution with encapsulated cells is stored
into the ink cartridge that is connected to a printer head.
The printer heads are deformed by a thermal or piezoelectric
actuators and squeezed to generate bioink droplets of controllable
size. However, to date, with very few exceptions (44), the
bioprinting has been barely explored to study the MSC and
cancer cells interactions.
Finally, tailored innovative platforms that combine spheroid
technologies with disease-specific in silico models by using
microfluidics, the so called “organ-on-a-chip” technologies that
reconstitute organ-level in vivo characteristics (45, 46), have
emerged also in cancer research. Although more expensive
and less practical, this cutting-edge approach facilitates the
identification of molecular mechanisms behind the disease or
the identification of novel biomarkers, and is also particularly
useful for drug screening. Microfluidics allows the study
of complex phenomena under the combination of multiple
biochemical and biophysical parameters, coupled with high-
resolution real-time imaging. This type of approach has been
mainly developed to study the interaction of tumour cells
with blood vessels that can be recreated in the microfluidic
chips. Few examples have also been reported for co-culturing
MSC with tumour cells, like for lung cancer (47), or to
recapitulate the bone metastatic niche that also includes MSC,
like for acute lymphoidmyeloma, acute lymphoblastic leukaemia,
or breast carcinoma (48–50). By using this approach, it is
possible to evaluate on real-time the induction of tumour
apoptosis, proliferation, migration and invasion, the activation
of the reactive stroma, the secretion of cytokines by tumour
cells, the activation of specific oncogenes, and stroma-mediated
extravasion and intravasion.
IN VIVO MODELS
To study the role of MSC on cancer development and
progression, several animal models has been developed,
mainly xenograft and syngenic small rodents, with MSC co-
injected with tumour cells (51–53). In these models, MSC
participate to tumour pathophysiology, ultimately facilitating
the metastatic spread of weakly metastatic cancer (52, 54–56).
MSC/tumour cells ratio seems to be particularly relevant like
for tumour dormancy/growth, as demonstrated in melanoma or
osteosarcoma models (57, 58). However, the isolation of MSC
with different methods and from different tissues (e.g., bone
marrow and adipose tissues) have made it difficult to reach
consistent conclusions.
Heterotopic injections are the most used and include the
subcutaneous injections (52), the easiest and most reproducible
model that rarely gives origin to metastases, and that is quite far
from the human disease since the host tissue surrounding the
tumor might be very different from the tumor-associated stroma
of the normal tissue where the tumor develops.
Systemically infused MSC localize within injured, inflamed,
and cancerous tissues. Thus, to study the tropism of MSC to
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TABLE 1 | 3D preclinical models to study the interaction between MSC and cancer cells.
Model General properties Advantages Disadvantages Applications of the
model
Forced-floating spheroids Aggregation induced by
preventing attachment
Low cost and high
reproducibility
Variability in cell size and
shape
High-throughput
investigations for efficacy
vs. toxicity of drugs
Hanging drop Aggregation induced by
agitation at the tip of a
drop formed by surface
tension
Relative low cost and high
reproducibility. Suitable for
drug screening and
high-throughput testing
The spheroid forms a necrotic
core
High-throughput drug
screening
Rotating cell culture bioreactors Forced spheroid formation
by continuous agitation
Easy to produce
spheroids on a large scale
Specialized equipment
required. Variability in size
and shape
Ideal for cells that require
long-term cultures and
controlled amounts of
nutrients and oxygen
Scaffold-based Cells are seeded within a
gel-like scaffold of natural
or synthetic origin
Provides a 3D support
that mimics the
physiological tissue for
ECM composition
Higher costs. Difficult to
retrieve cells from the
biomaterial. Lack
of reproducibility
3D structures where the
cells are free to migrate or
form in vivo-like cues
3D printing Cells are printed within
scaffold of natural or
synthetic origin
Provides a 3D support
that mimics the
physiological tissue for
ECM composition and the
spatial organization
Specialized equipment
required. Higher costs.
Difficult to retrieve cells from
the biomaterial. Lack
of reproducibility
Allow formation of
custom-specific ECMs or
scaffolds
Microfluidics Cells are seeded on
microfluidic device that, by
using multiple channel and
gel-like scaffolds perfused
by fluid medium
Provides a 3D support
that reconstitute
organ-level in vivo
characteristics. Live
observation.
Specialized equipment
required. Higher costs.
Difficult to retrieve cells from
the biomaterial. Lack of
reproducibility. N. of cells that
can be used is limited
Identification of molecular
cellular mechanisms or
biomarkers.
High-throughput drug
screening
the tumour, MSC have been injected into circulation through the
tail vein (59, 60). MSC have been also systemically administered
via alternative routes, like via intratracheal (61), internal carotid
artery (62), intraperitoneal (63), like for gliomas, breast, colon,
ovarian, and lung carcinomas (52, 53, 61–66). Systemic injection
of MSC may be useful also to enhance their viability along the
experiment. Indeed, as it appeared from studies on MSC-based
cell therapy, MSC survival is very low (67–70). Thus, periodic
injections of MSC after the first injection might enhance their
engraftment in the tumour and ensure the continuous secretion
of MSC-derived protein factors.
Finally, the use of orthotropic injection site mimics the fate
of MSC that have been already chemoattracted by tumour cells
and have migrated at the primary tumour site, and it better
recapitulates the human disease. However, this model has a great
variability and requires a higher number of animals to obtain
results that may be correctly interpreted.
It is clear that, due to the short-term survival of injected MSC,
monitoring their fate in vivo is crucial to support the conclusions
about their pro- or anti-cancer activities. As for tumour cells,
trackingMSC fate has been obtained by different approaches (see
Table 2). In principle, the most powerful technique should allow
non-invasive live imaging by optical or not-optical methods to
gain real-time information. After animal sacrifice, also histology,
immunofluorescence, immunohistochemistry, or flow cytometry
techniques on isolated live or fixed cells can be used. Among
the live-imaging techniques, the most used are the pre-labelling
of MSC with a lipophilic fluorescent dyes (e.g., DiL or Cell
TrackerTM) (54), or the pre-tagging of MSC by specific gene
transfection, like luciferase or green fluorescent protein for
the detection of bioluminescence (60, 71, 84) or fluorescence
(55), respectively. Notably, bioluminescent imaging of luciferase-
expressing cells is also a quantitative technique for the direct
assessment of tumour growth (51, 53), whereas non-optical
methods, such as magnetic resonance imaging (MRI) (82),
positron emission tomography (PET) (65) and single photon
emission computed tomography (SPECT) (83) provide a high
spatial resolution and three-dimensional whole-body imaging.
In conclusion, to develop a more clinical relevant in vivo
model that accurately reflects the human tumour biology is an
urgent need to better predict the response of the tumour to
the treatments and for identifying those steps that are crucial
for tumour progression to be targeted or prevented for an
improved clinical outcome. The addition of MSC in the model
is a step forward in this direction, although for the development
of in vivo pre-clinical models of MSC-tumour cells interaction
several parameters need to be carefully considered according
to the specific aim, like MSC:tumour cells ratio, the via of co-
injection, and the tracking of MSC to check their fate. Last
but not least, variables affecting the secretome should be very
carefully analysed.
THE SECRETOME
Studies onMSC-cancer interplay and analyses of cell conditioned
media in the mentioned preclinical models have allowed the
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TABLE 2 | Methods for imaging MSC-tumour interplay in vivo.
Method Cellular modification Contrast agent Model of
implantation
Tumour model Reference for
tracking MSC
Reference for
tracking tumour
cells
BLI-live imaging Luciferase transduction Bioluminescence
from
luciferase/luciferin
reaction
Orthotopic and
heterotopic
Osteosarcoma,
breast, ovarian
cancers
(53, 59, 60, 63, 71,
72)
(51, 73)
Fluorescent-live imaging GFP or fluorescent dye
labeling of membrane
Fluorescence from
fluorescent
proteins or
fluorescent dyes
Orthotopic and
heterotopic
Glioblastoma,
gliomas, breast,
colon carcinoma
(62, 64, 65, 74–77) (52, 62, 64, 65)
PET Genetic modification of
cells (PET reporter gene)
or uptake of radioisotope
labels
Positron-emitting
radionucleotides
Heterotopic Colon cancer,
clear cell sarcoma
(65, 72, 78–81)
MRI Magnetic nanoparticles
added to cells or coupled
to ligands
Superparamagnetic
iron oxide contrast
agent, internalized
iron, metal
chelates, etc.
Orthotopic and
heterotopic
Melanoma,
gliomas
(78, 82)
SPECT Uptake of radioisotope
labels
Radionucleotides
(gamma-emitting
radioisotopes)
Heterotopic Breast cancer (81, 83)
identification of solublemediators of the indirect communication
between MSC and tumour cells. To summarise, cancer cells
frequently secrete IL-1 and TGF-β which switch MSC to a pro-
inflammatory phenotype (85, 86), and the monocyte chemotactic
protein-1 (MCP-1) which stimulates MSC migration (87).
Conversely, MSC produce a plethora of cytokines which, in turn,
modulates cancer cell behaviour: IL-6 and IL-8 that promote
tumour cell proliferation, survival, migration, and invasion of
different tumour cells (26, 88–90), CCL5 that support metastasis
in several cancers (52, 91–93), the pro-angiogenic cytokine VEGF
that enhances tumour growth and metastasis (94, 95), and TGF-
β that fosters tumour invasion and metastasis via EMT (96).
Cell communication within the tumour microenvironment is
mediated also by exosomes, extracellular nanovesicles that deliver
a functional cargo of proteins, lipids, and nucleic acids (97).
Tumour-derived exosomes are able to co-opt and reprogram
MSC by enhancing their pro-tumourigenic functions, including
the pro-angiogenic activity and the production of the pro-
inflammatory cytokines IL6 (51, 98). On the other side, exosomes
derived from MSC are able to influence tumour development
(99), and to increase the tumour stemness (100). Besides, several
metabolites, like glutamine, lactate, and ketone bodies, that are
released both by tumours cells and by MSC in the extracellular
space might fuel the energetic metabolism of cells of the TME
(101) or may act as signalling molecules, ultimately stimulating
cancer motility, survival, or self-renewal (2, 102–106). Also in
osteosarcoma, we recently demonstrated that tumour cells cause
an oxidative stress in MSC that, in response, acquire a Warburg
phenotype and produce a large amount of lactate.
In this context, it is worth to highlight that the in vitro
conditions, both 2D and 3D, might induce secretory
modifications per se (107), thereby affecting the interpretation
of results, like by using experimental conditions that can
unintentionally exert a stressing stimulus for the cells. Thus, we
suggest to evaluate results by considering cells, secretome, and
three-dimension as an integrated whole. This add complexity
to the system, and careful attention has to be paid when setting
up the experiment according to the specific aim and during the
interpretation of data.
CONCLUSIONS
Several model systems are now available to characterize the
MSC-tumour interplay in the TME. These offer early promise
in establishing robust preclinical platforms for the identification
of crucial molecular pathways and for the assessment of
clinical efficacy of novel drugs to inhibit cancer development
and progression. However, selection of the right model for
a given study should be shaped on the purpose, and should
also consider fixed biological, biochemical, and biophysical
parameters according to the specific tumour type. Finally,
in order to get reliable and useful results to be translated
to the clinic, it should be always kept in mind the careful
comparisons in the prediction of human outcomes by the
developed model.
AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual
contribution to the work, and approved it for publication.
FUNDING
This study was funded by the Italian Association for Cancer
Research (AIRC IG# 21403 to NB) and by the Ministry of Health
5x1000 fundings (to NB at Rizzoli Orthopaedic Institute).
Frontiers in Oncology | www.frontiersin.org 5 April 2019 | Volume 9 | Article 305
Avnet et al. MSC-Cancer Cells Interactions: Pre-clinical Models
REFERENCES
1. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in
conversion of normal to malignant breast: importance of the stromal
reaction. Physiol Rev. (1996) 76:69–125. doi: 10.1152/physrev.1996.76.1.69
2. Hui L, Chen Y. Tumor microenvironment: Sanctuary of the devil. Cancer
Lett. (2015) 368:7–13. doi: 10.1016/j.canlet.2015.07.039
3. Barclay M, Skipski VP, Terebus-Kekish O, Merker PL, Cappuccino JG.
Serum lipoproteins in rats with tumors induced by 9,10-dimethyl-1,2-
benzanthracene and with transplanted Walker carcinosarcoma 256. Cancer
Res. (1967) 27:1158–67.
4. Borriello L, Nakata R, Sheard MA, Fernandez GE, Sposto R, Malvar J,
et al. Cancer-associated fibroblasts share characteristics and protumorigenic
activity with mesenchymal stromal cells. Cancer Res. (2017) 77:5142–57.
doi: 10.1158/0008-5472.CAN-16-2586
5. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer.
(2016) 16:582–98. doi: 10.1038/nrc.2016.73
6. Kidd S, Spaeth E, Klopp A, Andreeff M, Hall B, Marini FC. The (in)
auspicious role of mesenchymal stromal cells in cancer: be it friend or foe.
Cytotherapy. (2008) 10:657–67. doi: 10.1080/14653240802486517
7. Gok Yavuz B, Gunaydin G, Gedik ME, Kosemehmetoglu K,
Karakoc D, Ozgur F, et al. Cancer associated fibroblasts sculpt
tumour microenvironment by recruiting monocytes and inducing
immunosuppressive PD-1(+) TAMs. Sci Rep. (2019) 9:3172.
doi: 10.1038/s41598-019-39553-z
8. Kfoury Y, Scadden DT. Mesenchymal cell contributions to the stem cell
niche. Cell Stem Cell. (2015) 16:239–53. doi: 10.1016/j.stem.2015.02.019
9. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al.
A cell initiating human acute myeloid leukaemia after transplantation into
SCID mice. Nature. (1994) 367:645–8. doi: 10.1038/367645a0
10. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, et al.
Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia.
(2005) 7:967–76. doi: 10.1593/neo.05394
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke
MF. Prospective identification of tumorigenic breast cancer cells.
Proc Natl Acad Sci USA. (2003) 100:3983–8. doi: 10.1073/pnas.05302
91100
12. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C,
et al. Identification and expansion of human colon-cancer-initiating cells.
Nature. (2007) 445:111–5. doi: 10.1038/nature05384
13. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al.
Cancer stem cells–perspectives on current status and future directions:
AACR Workshop on cancer stem cells. Cancer Res. (2006) 66:9339–44.
doi: 10.1158/0008-5472.CAN-06-3126
14. Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. (2017) 23:1124–34.
doi: 10.1038/nm.4409
15. Shamai Y, Alperovich DC, Yakhini Z, Skorecki K, Tzukerman M. Reciprocal
reprogramming of cancer cells and associated mesenchymal stem cells in
gastric cancer. Stem Cells. (2019) 37:176–89. doi: 10.1002/stem.2942
16. Yang Y, Otte A, Hass R. Human mesenchymal stroma/stem cells
exchange membrane proteins and alter functionality during interaction
with different tumor cell lines. Stem Cells Dev. (2015) 24:1205–22.
doi: 10.1089/scd.2014.0413
17. Wei HJ, Nickoloff JA, Chen WH, Liu HY, Lo WC, Chang YT, et al. FOXF1
mediates mesenchymal stem cell fusion-induced reprogramming of lung
cancer cells. Oncotarget. (2014) 5:9514–29. doi: 10.18632/oncotarget.2413
18. Xue J, Zhu Y, Sun Z, Ji R, Zhang X, Xu W, et al. Tumorigenic
hybrids between mesenchymal stem cells and gastric cancer cells enhanced
cancer proliferation, migration and stemness. BMC Cancer. (2015) 15:793.
doi: 10.1186/s12885-015-1780-1
19. Melzer C, Yang Y, Hass R. Interaction ofMSCwith tumor cells.Cell Commun
Signal. (2016) 14:20. doi: 10.1186/s12964-016-0143-0
20. Melzer C, von der Ohe J, Lehnert H, Ungefroren H, Hass R. Cancer stem
cell niche models and contribution by mesenchymal stroma/stem cells. Mol
Cancer. (2017) 16:28. doi: 10.1186/s12943-017-0595-x
21. Sottile F, Aulicino F, Theka I, Cosma MP. Mesenchymal stem cells generate
distinct functional hybrids in vitro via cell fusion or entosis. Sci Rep. (2016)
6:36863. doi: 10.1038/srep36863
22. Cortini M, Avnet S, Baldini N. Mesenchymal stroma: role in osteosarcoma
progression. Cancer Lett. (2017) 405:90–9. doi: 10.1016/j.canlet.2017.07.024
23. Fessler E, Dijkgraaf FE, De Sousa EMF, Medema JP. Cancer stem cell
dynamics in tumor progression and metastasis: is the microenvironment to
blame? Cancer Lett. (2013) 341:97–104. doi: 10.1016/j.canlet.2012.10.015
24. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The
epithelial-mesenchymal transition generates cells with properties of stem
cells. Cell. (2008) 133:704–15. doi: 10.1016/j.cell.2008.03.027
25. Salerno M, Avnet S, Bonuccelli G, Eramo A, De Maria R, Gambarotti
M, et al. Sphere-forming cell subsets with cancer stem cell properties
in human musculoskeletal sarcomas. Int J Oncol. (2013) 43:95–102.
doi: 10.3892/ijo.2013.1927
26. Cortini M, Massa A, Avnet S, Bonuccelli G, Baldini N. Tumor-
activated mesenchymal stromal cells promote osteosarcoma stemness and
migratory potential via IL-6 secretion. PLoS ONE. (2016) 11:e0166500.
doi: 10.1371/journal.pone.0166500
27. Zhang H, Wu H, Zheng J, Yu P, Xu L, Jiang P, et al. Transforming
growth factor beta1 signal is crucial for dedifferentiation of cancer cells
to cancer stem cells in osteosarcoma. Stem Cells. (2013) 31:433–46.
doi: 10.1002/stem.1298
28. Iser IC, Ceschini SM, Onzi GR, Bertoni AP, Lenz G, Wink MR. Conditioned
medium from adipose-derived stem cells (ADSCs) promotes epithelial-
to-mesenchymal-like transition (EMT-Like) in glioma cells in vitro. Mol
Neurobiol. (2016) 53:7184–99. doi: 10.1007/s12035-015-9585-4
29. Hernanda PY, Pedroza-Gonzalez A, van der Laan LJ, Broker ME, Hoogduijn
MJ, Ijzermans JN, et al. Tumor promotion through the mesenchymal
stem cell compartment in human hepatocellular carcinoma. Carcinogenesis.
(2013) 34:2330–40. doi: 10.1093/carcin/bgt210
30. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM.
Interleukin-6 is a potent growth factor for ER-alpha-positive human breast
cancer. FASEB J. (2007) 21:3763–70. doi: 10.1096/fj.07-8832com
31. Avnet S, Di Pompo G, Chano T, Errani C, Ibrahim-Hashim A, Gillies
RJ, et al. Cancer-associated mesenchymal stroma fosters the stemness of
osteosarcoma cells in response to intratumoral acidosis via NF-kappaB
activation. Int J Cancer. (2017) 140:1331–45. doi: 10.1002/ijc.30540
32. Chiovaro F, Martina E, Bottos A, Scherberich A, Hynes NE, Chiquet-
Ehrismann R. Transcriptional regulation of tenascin-W by TGF-beta
signaling in the bone metastatic niche of breast cancer cells. Int J Cancer.
(2015) 137:1842–54. doi: 10.1002/ijc.29565
33. Caicedo A, Fritz V, Brondello JM, AyalaM, Dennemont I, Abdellaoui N, et al.
MitoCeption as a new tool to assess the effects of mesenchymal stem/stromal
cell mitochondria on cancer cell metabolism and function. Sci Rep. (2015)
5:9073. doi: 10.1038/srep09073
34. Bonuccelli G, Avnet S, Grisendi G, Salerno M, Granchi D, Dominici
M, et al. Role of mesenchymal stem cells in osteosarcoma and
metabolic reprogramming of tumor cells. Oncotarget. (2014) 5:7575–88.
doi: 10.18632/oncotarget.2243
35. Molloy AP, Martin FT, Dwyer RM, Griffin TP, Murphy M, Barry FP, et al.
Mesenchymal stem cell secretion of chemokines during differentiation into
osteoblasts, and their potential role in mediating interactions with breast
cancer cells. Int J Cancer. (2009) 124:326–32. doi: 10.1002/ijc.23939
36. Ishiguro T, Ohata H, Sato A, Yamawaki K, Enomoto T, Okamoto K. Tumor-
derived spheroids: Relevance to cancer stem cells and clinical applications.
Cancer Sci. (2017) 108:283–9. doi: 10.1111/cas.13155
37. Lin RZ, Chang HY. Recent advances in three-dimensional multicellular
spheroid culture for biomedical research. Biotechnol J. (2008) 3:1172–84.
doi: 10.1002/biot.200700228
38. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in
3D. Cell. (2007) 130:601–10. doi: 10.1016/j.cell.2007.08.006
39. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser
W, Kunz-Schughart LA. Multicellular tumor spheroids: an
underestimated tool is catching up again. J Biotechnol. (2010) 148:3–15.
doi: 10.1016/j.jbiotec.2010.01.012
40. Kim JB. Three-dimensional tissue culture models in cancer biology. Semin
Cancer Biol. (2005) 15:365–77. doi: 10.1016/j.semcancer.2005.05.002
41. Breslin S, O’Driscoll L. Three-dimensional cell culture: the missing
link in drug discovery. Drug Discov Today. (2013) 18:240–9.
doi: 10.1016/j.drudis.2012.10.003
Frontiers in Oncology | www.frontiersin.org 6 April 2019 | Volume 9 | Article 305
Avnet et al. MSC-Cancer Cells Interactions: Pre-clinical Models
42. Saforo D, Omer L, Smolenkov A, Barve A, Casson L, Boyd N, et al. Primary
lung cancer samples cultured under microenvironment-mimetic conditions
enrich for mesenchymal stem-like cells that promote metastasis. Sci Rep.
(2019) 9:4177. doi: 10.1038/s41598-019-40519-4
43. Zhang YS, Duchamp M, Oklu R, Ellisen LW, Langer R, Khademhosseini A.
Bioprinting the Cancer Microenvironment. ACS Biomater Sci Eng. (2016)
2:1710–21. doi: 10.1021/acsbiomaterials.6b00246
44. Braham MVJ, Ahlfeld T, Akkineni AR, Minnema MC, Dhert WJA, Oner
FC, et al. Endosteal and perivascular subniches in a 3D bone marrow
model for multiple myeloma. Tissue Eng Part C Methods. (2018) 24:300–12.
doi: 10.1089/ten.tec.2017.0467
45. Portillo-Lara R, Annabi N. Microengineered cancer-on-a-chip platforms
to study the metastatic microenvironment. Lab Chip. (2016) 16:4063–81.
doi: 10.1039/C6LC00718J
46. Chung M, Ahn J, Son K, Kim S, Jeon NL. Biomimetic model of tumor
microenvironment on microfluidic platform. Adv Healthc Mater. (2017)
6:196. doi: 10.1002/adhm.201700196
47. Hao Y, Zhang L, He J, Guo Z, Ying L, Xu Z, et al. Functional investigation
of NCI-H460-inducible myofibroblasts on the chemoresistance to VP-16
with a microfluidic 3D co-culture device. PLoS ONE. (2013) 8:e61754.
doi: 10.1371/journal.pone.0061754
48. Narkhede AA, Shevde LA, Rao SS. Biomimetic strategies to recapitulate
organ specific microenvironments for studying breast cancer metastasis. Int
J Cancer. (2017) 141:1091–109. doi: 10.1002/ijc.30748
49. Houshmand M, Soleimani M, Atashi A, Saglio G, Abdollahi M, Nikougoftar
Zarif M. Mimicking the acute myeloid leukemia niche for molecular
study and drug screening. Tissue Eng Part C Methods. (2017) 23:72–85.
doi: 10.1089/ten.tec.2016.0404
50. Bersini S, Jeon JS, Dubini G, Arrigoni C, Chung S, Charest
JL, et al. A microfluidic 3D in vitro model for specificity of
breast cancer metastasis to bone. Biomaterials. (2014) 35:2454–61.
doi: 10.1016/j.biomaterials.2013.11.050
51. Baglio SR, Lagerweij T, Perez-Lanzon M, Ho XD, Leveille N, Melo
SA, et al. Blocking tumor-educated MSC paracrine activity halts
osteosarcoma progression. Clin Cancer Res. (2017) 23:3721–33.
doi: 10.1158/1078-0432.CCR-16-2726
52. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW,
et al. Mesenchymal stem cells within tumour stroma promote breast
cancer metastasis. Nature. (2007) 449:557–63. doi: 10.1038/nature
06188
53. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F,
et al. Breast cancer stem cells are regulated by mesenchymal stem
cells through cytokine networks. Cancer Res. (2011) 71:614–24.
doi: 10.1158/0008-5472.CAN-10-0538
54. Zhang P, Dong L, Long H, Yang TT, Zhou Y, Fan QY, et al. Homologous
mesenchymal stem cells promote the emergence and growth of pulmonary
metastases of the rat osteosarcoma cell line UMR-106. Oncol Lett. (2014)
8:127–32. doi: 10.3892/ol.2014.2127
55. Ke CC, Liu RS, Suetsugu A, Kimura H, Ho JH, Lee OK, et al.
In vivo fluorescence imaging reveals the promotion of mammary
tumorigenesis by mesenchymal stromal cells. PLoS ONE. (2013) 8:e69658.
doi: 10.1371/journal.pone.0069658
56. Fregni G, Quinodoz M, Moller E, Vuille J, Galland S, Fusco C,
et al. Reciprocal modulation of mesenchymal stem cells and tumor
cells promotes lung cancer metastasis. EBioMedicine. (2018) 29:128–45.
doi: 10.1016/j.ebiom.2018.02.017
57. Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. Tumor
cell behaviour modulation bymesenchymal stromal cells.Mol Cancer. (2010)
9:129. doi: 10.1186/1476-4598-9-129
58. Avril P, Le Nail LR, Brennan MA, Rosset P, De Pinieux G, Layrolle P,
et al. Mesenchymal stem cells increase proliferation but do not change
quiescent state of osteosarcoma cells: potential implications according to the
tumor resection status. J Bone Oncol. (2016) 5:5–14. doi: 10.1016/j.jbo.2015.
11.002
59. Wang H, Cao F, De A, Cao Y, Contag C, Gambhir SS, et al.
Traffickingmesenchymal stem cell engraftment and differentiation in tumor-
bearing mice by bioluminescence imaging. Stem Cells. (2009) 27:1548–58.
doi: 10.1002/stem.81
60. Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn
RE, et al. Tumor irradiation increases the recruitment of circulating
mesenchymal stem cells into the tumor microenvironment. Cancer Res.
(2007) 67:11687–95. doi: 10.1158/0008-5472.CAN-07-1406
61. Xin H, Sun R, Kanehira M, Takahata T, Itoh J, Mizuguchi H,
et al. Intratracheal delivery of CX3CL1-expressing mesenchymal
stem cells to multiple lung tumors. Mol Med. (2009) 15:321–7.
doi: 10.2119/molmed.2009.00059
62. Nakamizo A,Marini F, Amano T, Khan A, StudenyM, Gumin J, et al. Human
bone marrow-derived mesenchymal stem cells in the treatment of gliomas.
Cancer Res. (2005) 65:3307–18. doi: 10.1158/0008-5472.CAN-04-1874
63. Komarova S, Roth J, Alvarez R, Curiel DT, Pereboeva L. Targeting of
mesenchymal stem cells to ovarian tumors via an artificial receptor. J Ovarian
Res. (2010) 3:12. doi: 10.1186/1757-2215-3-12
64. Goldstein RH, Reagan MR, Anderson K, Kaplan DL, Rosenblatt M.
Human bone marrow-derived MSCs can home to orthotopic breast cancer
tumors and promote bone metastasis. Cancer Res. (2010) 70:10044–50.
doi: 10.1158/0008-5472.CAN-10-1254
65. Hung SC, Deng WP, Yang WK, Liu RS, Lee CC, Su TC, et al. Mesenchymal
stem cell targeting of microscopic tumors and tumor stroma development
monitored by noninvasive in vivo positron emission tomography imaging.
Clin Cancer Res. (2005) 11:7749–56. doi: 10.1158/1078-0432.CCR-05-0876
66. Loebinger MR, Kyrtatos PG, Turmaine M, Price AN, Pankhurst Q, Lythgoe
MF, et al. Magnetic resonance imaging of mesenchymal stem cells homing to
pulmonary metastases using biocompatible magnetic nanoparticles. Cancer
Res. (2009) 69:8862–7. doi: 10.1158/0008-5472.CAN-09-1912
67. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the
details. Cell Stem Cell. (2009) 4:206–16. doi: 10.1016/j.stem.2009.02.001
68. Kean TJ, Lin P, Caplan AI, Dennis JE. MSCs: Delivery routes and
engraftment, cell-targeting strategies, and immune modulation. Stem Cells
Int. (2013) 2013:732742. doi: 10.1155/2013/732742
69. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt
HJ, et al. Mesenchymal stem cells are short-lived and do not migrate
beyond the lungs after intravenous infusion. Front Immunol. (2012) 3:297.
doi: 10.3389/fimmu.2012.00297
70. Braid LR, Wood CA, Wiese DM, Ford BN. Intramuscular administration
potentiates extended dwell time of mesenchymal stromal cells compared to
other routes. Cytotherapy. (2018) 20:232–44. doi: 10.1016/j.jcyt.2017.09.013
71. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, et al.
Direct evidence of mesenchymal stem cell tropism for tumor and wounding
microenvironments using in vivo bioluminescent imaging. Stem Cells. (2009)
27:2614–23. doi: 10.1002/stem.187
72. Love Z, Wang F, Dennis J, Awadallah A, Salem N, Lin Y, et al. Imaging of
mesenchymal stem cell transplant by bioluminescence and PET. J Nucl Med.
(2007) 48:2011–20. doi: 10.2967/jnumed.107.043166
73. Kim JB, Urban K, Cochran E, Lee S, Ang A, Rice B, et al. Non-invasive
detection of a small number of bioluminescent cancer cells in vivo. PLoS
ONE. (2010) 5:e9364. doi: 10.1371/journal.pone.0009364
74. Pacioni S, D’Alessandris QG, Giannetti S, Morgante L, Cocce V, Bonomi
A, et al. Human mesenchymal stromal cells inhibit tumor growth in
orthotopic glioblastoma xenografts. Stem Cell Res Ther. (2017) 8:53.
doi: 10.1186/s13287-017-0516-3
75. Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L,
et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-
like migratory vehicles in experimental gliomas.Mol Ther. (2009) 17:183-90.
doi: 10.1038/mt.2008.229
76. Wang N, Fallavollita L, Nguyen L, Burnier J, Rafei M, Galipeau J, et al.
Autologous bone marrow stromal cells genetically engineered to secrete an
igf-I receptor decoy prevent the growth of liver metastases.Mol Ther. (2009)
17:1241–9. doi: 10.1038/mt.2009.82
77. Pavon LF, Sibov TT, de Souza AV, da Cruz EF, Malheiros SMF, Cabral FR,
et al. Tropism of mesenchymal stem cell toward CD133(+) stem cell of
glioblastoma in vitro and promote tumor proliferation in vivo. Stem Cell Res
Ther. (2018) 9:310. doi: 10.1186/s13287-018-1049-0
78. Patel D, Kell A, Simard B, Xiang B, Lin HY, Tian G. The cell
labeling efficacy, cytotoxicity and relaxivity of copper-activated
MRI/PET imaging contrast agents. Biomaterials. (2011) 32:1167–76.
doi: 10.1016/j.biomaterials.2010.10.013
Frontiers in Oncology | www.frontiersin.org 7 April 2019 | Volume 9 | Article 305
Avnet et al. MSC-Cancer Cells Interactions: Pre-clinical Models
79. Yaghoubi SS, Gambhir SS. PET imaging of herpes simplex virus type
1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk reporter gene
expression in mice and humans using [18F]FHBG. Nat Protoc. (2006)
1:3069–75. doi: 10.1038/nprot.2006.459
80. Schonitzer V, Haasters F, Kasbauer S, Ulrich V, Mille E, Gildehaus FJ,
et al. In vivo mesenchymal stem cell tracking with PET using the
dopamine type 2 receptor and 18F-fallypride. J Nucl Med. (2014) 55:1342–7.
doi: 10.2967/jnumed.113.134775
81. Lim M, Wang W, Liang L, Han ZB, Li Z, Geng J, et al. Intravenous injection
of allogeneic umbilical cord-derived multipotent mesenchymal stromal cells
reduces the infarct area and ameliorates cardiac function in a porcine
model of acute myocardial infarction. Stem Cell Res Ther. (2018) 9:129.
doi: 10.1186/s13287-018-0888-z
82. Wu X, Hu J, Zhou L, Mao Y, Yang B, Gao L, et al. In vivo tracking
of superparamagnetic iron oxide nanoparticle-labeled mesenchymal
stem cell tropism to malignant gliomas using magnetic resonance
imaging. Laboratory investigation. J Neurosurg. (2008) 108:320–9.
doi: 10.3171/JNS/2008/108/2/0320
83. Dwyer RM, Ryan J, Havelin RJ, Morris JC, Miller BW, Liu Z, et al.
Mesenchymal Stem Cell-mediated delivery of the sodium iodide symporter
supports radionuclide imaging and treatment of breast cancer. Stem Cells.
(2011) 29:1149–57. doi: 10.1002/stem.665
84. Compte M, Cuesta AM, Sanchez-Martin D, Alonso-Camino V, Vicario
JL, Sanz L, et al. Tumor immunotherapy using gene-modified human
mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds.
Stem Cells. (2009) 27:753–60. doi: 10.1634/stemcells.2008-0831
85. Li HJ, Reinhardt F, Herschman HR, Weinberg RA. Cancer-
stimulated mesenchymal stem cells create a carcinoma stem cell
niche via prostaglandin E2 signaling. Cancer Discov. (2012) 2:840–55.
doi: 10.1158/2159-8290.CD-12-0101
86. Tu B, Peng ZX, Fan QM, Du L, Yan W, Tang TT. Osteosarcoma cells
promote the production of pro-tumor cytokines in mesenchymal stem cells
by inhibiting their osteogenic differentiation through the TGF-beta/Smad2/3
pathway. Exp Cell Res. (2014) 320:164–73. doi: 10.1016/j.yexcr.2013.10.013
87. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E,
Murphy JM, et al. Monocyte chemotactic protein-1 secreted by primary
breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer
Res. (2007) 13:5020–7. doi: 10.1158/1078-0432.CCR-07-0731
88. Touboul C, Lis R, Al Farsi H, Raynaud CM, Warfa M, Althawadi H, et al.
Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6
secretion in an amniochorionic membrane based 3D model. J Transl Med.
(2013) 11:28. doi: 10.1186/1479-5876-11-28
89. Walter M, Liang S, Ghosh S, Hornsby PJ, Li R. Interleukin 6 secreted from
adipose stromal cells promotes migration and invasion of breast cancer cells.
Oncogene. (2009) 28:2745–55. doi: 10.1038/onc.2009.130
90. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M,
et al. IL-6 triggers malignant features in mammospheres from human
ductal breast carcinoma and normal mammary gland. J Clin Invest. (2007)
117:3988–4002. doi: 10.1172/JCI32533
91. Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin
promotes CCL5-mesenchymal stromal cell-mediated breast cancer
metastasis. Carcinogenesis. (2011) 32:477–87. doi: 10.1093/carcin/bgr009
92. Luo J, Ok Lee S, Liang L, Huang CK, Li L, Wen S, et al. Infiltrating
bone marrow mesenchymal stem cells increase prostate cancer stem
cell population and metastatic ability via secreting cytokines to
suppress androgen receptor signaling. Oncogene. (2014) 33:2768–78.
doi: 10.1038/onc.2013.233
93. Xu WT, Bian ZY, Fan QM, Li G, Tang TT. Human mesenchymal stem
cells (hMSCs) target osteosarcoma and promote its growth and pulmonary
metastasis. Cancer Lett. (2009) 281:32–41. doi: 10.1016/j.canlet.2009.02.022
94. Beckermann BM, Kallifatidis G, Groth A, Frommhold D, Apel A, Mattern
J, et al. VEGF expression by mesenchymal stem cells contributes to
angiogenesis in pancreatic carcinoma. Br J Cancer. (2008) 99:622–31.
doi: 10.1038/sj.bjc.6604508
95. Zhang K, Shi B, Chen J, Zhang D, Zhu Y, Zhou C, et al. Bone marrow
mesenchymal stem cells induce angiogenesis and promote bladder cancer
growth in a rabbit model. Urol Int. (2010) 84:94–9. doi: 10.1159/000
273474
96. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal
transition. Cell Res. (2009) 19:156–72. doi: 10.1038/cr.2009.5
97. Ruivo CF, Adem B, Silva M, Melo SA. The biology of cancer
exosomes: insights and new perspectives. Cancer Res. (2017) 77:6480–8.
doi: 10.1158/0008-5472.CAN-17-0994
98. Whiteside TL. Exosome and mesenchymal stem cell cross-talk in
the tumor microenvironment. Semin Immunol. (2018) 35:69–79.
doi: 10.1016/j.smim.2017.12.003
99. Qi J, Zhou Y, Jiao Z, Wang X, Zhao Y, Li Y, et al. Exosomes derived
from human bone marrow mesenchymal stem cells promote tumor growth
through hedgehog signaling pathway. Cell Physiol Biochem. (2017) 42:2242–
54. doi: 10.1159/000479998
100. Li H, Li F. Exosomes from BM-MSCs increase the population of
CSCs via transfer of miR-142-3p. Br J Cancer. (2018) 119:744–55.
doi: 10.1038/s41416-018-0254-z
101. Wilde L, Roche M, Domingo-Vidal M, Tanson K, Philp N, Curry J, et al.
Metabolic coupling and the Reverse Warburg Effect in cancer: Implications
for novel biomarker and anticancer agent development. Semin Oncol. (2017)
44:198–203. doi: 10.1053/j.seminoncol.2017.10.004
102. Corbet C, Feron O. Cancer cell metabolism and mitochondria: nutrient
plasticity for TCA cycle fueling. Biochim Biophys Acta Rev Cancer. (2017)
1868:7–15. doi: 10.1016/j.bbcan.2017.01.002
103. Danhier P, Banski P, Payen VL, Grasso D, Ippolito L, Sonveaux P, et al. Cancer
metabolism in space and time: beyond the Warburg effect. Biochim Biophys
Acta Bioenerg. (2017) 1858:556–72. doi: 10.1016/j.bbabio.2017.02.001
104. Chiarugi P, Cirri P. Metabolic exchanges within tumor microenvironment.
Cancer Lett. (2016) 380:272–80. doi: 10.1016/j.canlet.2015.
10.027
105. Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-
associated fibroblasts transfer energy and biomass to anabolic cancer
cells, fueling tumor growth. Semin Cancer Biol. (2014) 25:47–60.
doi: 10.1016/j.semcancer.2014.01.005
106. Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis
A, et al. Reciprocal metabolic reprogramming through lactate shuttle
coordinately influences tumor-stroma interplay.Cancer Res. (2012) 72:5130–
40. doi: 10.1158/0008-5472.CAN-12-1949
107. Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal
stem cell secretome: toward cell-free therapeutic strategies in
regenerative medicine. Int J Mol Sci. (2017) 18:1852. doi: 10.3390/ijms1
8091852
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Avnet, Lemma, Cortini, Di Pompo, Perut and Baldini. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Oncology | www.frontiersin.org 8 April 2019 | Volume 9 | Article 305
